Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren's disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren's therapy.
In serving some of the most vulnerable and sick patient populations, this comprehensive approach can lead to improved outcomes while focusing on slowing disease progression.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
Lark Health, which offers AI-powered digital care platforms for chronic diseases, has raised $70 million in new funds, which it plans to use to expand its relationship with Anthem and eventually deepen partnerships with other payers and telehealth providers.